Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2012

View Archived Issues

New phase I data disclosed on KX2-391 in chemotherapy-naive bone-metastatic CRPC

OMP-59R5 well tolerated in phase I study

CalciMedica describes new class of immunomodulators

Clinical studies assess daily and twice-daily dosing of golvatinib

CHMP schedules hearing for Vivus' Qnexa MAA

Novel candidate cancer therapies created at Aurigene Discovery Technologies

Research alliance reached for carfilzomib and oprozomib

Phase III elagolix study begins in endometriosis

MebioPharm set to launch phase II/III MBP-426 trial

Portola Pharmaceuticals presents new SYK inhibitors

Dr. Reddy's Laboratories enters worldwide biosimilars collaboration

PharmaGap provides update on lead program

Roche expands gantenerumab trial in prodromal Alzheimer's disease

Preclinical study validates new target for resistant tumors

Phase I study evaluates peptide vaccine including cancer/testis antigens

Bayer designs novel guanylate cyclase activators

FDA sends complete response letter for ridaforolimus NDA

BioDiem to license new vaccine technology from Australian university

Kythera receives milestone payment from Bayer in ATX-101 collaboration

Research at U.S. university yields new anticancer agents

ProFibrix commences pivotal FINISH-3 study

Starpharma provides enrollment update for pivotal VivaGel studies

AVEO and Astellas planning new phase II study in RCC

Novel protein kinase inhibitors divulged

SDF-1 inhibition may limit transplant vasculopathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...